AIDS Drug Tender Controversy Raises Serious Questions
Delve into the AIDS Drug Tender Controversy where Motsoaledi points to the DG in the R15.5bn ARV procurement scandal.
Lenacapavir HIV Prevention Injection to Reach Too Few
South Africa’s first consignment of lenacapavir, a six-monthly HIV prevention injection for high-risk HIV-negative people, will cover fewer than a quarter of the target population. Deliveries are underway and will continue through April. Rollout will begin immediately after delivery, with an initial two-year implementation plan…. Membership Required You must be a member to access this...
AIDS Drug Tender: Pressure as Suppliers Enter Business Rescue
The AIDS drug tender reveals challenges in supply continuity due to Avacare subsidiaries entering business rescue.
HIV Drug Tender Facing Legal Challenge from Hetero SA
Hetero SA challenges the HIV drug tender decision in court, claiming exclusion from vital antiretroviral supply contracts.
UK Cuts Contribution to Global Fund By 15 Percent
The UK cuts contribution to the Global Fund by 15%, reducing support for critical health initiatives amid budget challenges.
Lenacapavir Approved for HIV Prevention in South Africa
Lenacapavir has been registered by SAHPRA as an innovative HIV prevention injection. Find out more about its rollout in South Africa.
African Philanthropists Must Drive Change in Public Health
Understand how African philanthropists can lead the way in health improvement efforts, saving lives and supporting innovation.
UNAIDS Closure Causes Outrage Among Health Advocates
Activists warn that the UNAIDS closure will critically affect HIV/AIDS progress, calling for urgent global health action.
Generic HIV Prevention Drug to Cost Just $40 Annually from 2027
Explore the benefits of the generic HIV prevention drug lenacapavir, set to change the landscape of global health by 2027.
End of UNAIDS Looms as UN Proposes Agency Closure by 2026
Explore the implications of the end of UNAIDS by 2026 amid a funding crisis in the global HIV/AIDS response.